Effect of Imatinib treatment on renal anaemia in chronic myeloid leukemia patients
- 2 March 2023
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 29 (8) , 1928-1934
Abstract
Purpose: In this study, we investigate renal function and anaemia during imatinib treatment in patients with chronic myeloid leukaemia. Methods: The patients with chronic myeloid leukaemia with chronic phase who had been treated with only imatinib for 12 months at Rajiv Gandhi Cancer Institute and Research Centre (New Delhi, India) were enrolled and prospectively analysed. The chronic renal impairment parameters, including estimated glomerular filtration rate and haemoglobin levels for anaemia from June 2020 to June 2022, were monitored in newly diagnosed in patients with chronic myeloid leukaemia-chronic phase. The data were analysed by SPSS software version 22. Results: In total 55 patients with chronic myeloid leukaemia chronic phase who had been on imatinib for 12 months were monitored. The mean estimated glomerular filtration rate was significantly decreased (74 ± 14 to 59 ± 12 mL/min/1.73m2, p < 0.001) with a decrease in mean haemoglobin levels after 12 months (10.9 ± 2.01 to 9.0 ± 1.02, p < 0.004). The decreased estimated glomerular filtration rate was negatively correlated with haemoglobin levels after 1 year of imatinib administration (correlation coefficient = 0.892, R2 = 0.7976, p < 0.05). Conclusion: We recommended close monitoring of renal function and haemoglobin levels in patients with chronic myeloid leukaemia patients.Keywords
This publication has 37 references indexed in Scilit:
- Management of imatinib-resistant patients with chronic myeloid leukemiaTherapeutic Advances in Hematology, 2012
- Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patientsAnnals of Oncology, 2011
- Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phaseBiologics: Targets and Therapy, 2010
- Imatinib front‐line therapy is safe and effective in patients with chronic myelogenous leukemia with pre‐existing liver and/or renal dysfunctionCancer, 2010
- Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA groupHaematologica, 2010
- Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phaseCancer, 2009
- Biosimilar therapeutics--what do we need to consider?NDT Plus, 2009
- Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations of Existing TherapiesMayo Clinic Proceedings, 2007
- The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic ActivityJournal of Experimental Medicine, 1999
- Chronic Renal Failure — A Vasculopathic StateNew England Journal of Medicine, 1998